Company registration number 11277994 (England and Wales)
BRENT PHARMA LIMITED
UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2025
PAGES FOR FILING WITH REGISTRAR
BRENT PHARMA LIMITED
CONTENTS
Page
Balance sheet
1 - 2
Notes to the financial statements
3 - 6
BRENT PHARMA LIMITED
BALANCE SHEET
AS AT 31 MARCH 2025
31 March 2025
- 1 -
2025
2024
Notes
£
£
£
£
Fixed assets
Intangible assets
3
1
1
Tangible assets
4
13,405
12,197
13,406
12,198
Current assets
Stocks
34,378
28,522
Debtors
5
249,797
256,038
Cash at bank and in hand
333,170
205,434
617,345
489,994
Creditors: amounts falling due within one year
6
(362,636)
(313,731)
Net current assets
254,709
176,263
Total assets less current liabilities
268,115
188,461
Provisions for liabilities
(3,351)
(3,049)
Net assets
264,764
185,412
Capital and reserves
Called up share capital
1
1
Profit and loss reserves
264,763
185,411
Total equity
264,764
185,412
BRENT PHARMA LIMITED
BALANCE SHEET (CONTINUED)
AS AT 31 MARCH 2025
31 March 2025
- 2 -

For the financial year ended 31 March 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

T he members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.

The director acknowledges his responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The director of the company has elected not to include a copy of the profit and loss account within the financial statements.true

The financial statements were approved and signed by the director and authorised for issue on 17 November 2025
Mr M Shamoon
Director
Company registration number 11277994 (England and Wales)
BRENT PHARMA LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2025
- 3 -
1
Accounting policies
Company information

Brent Pharma Limited is a private company limited by shares incorporated in England and Wales. The registered office is 214 High Street, Brentford, Middlesex, TW8 8AH.

1.1
Accounting convention

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary a mounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention, [modified to include the revaluation of freehold properties and to include investment properties and certain financial instruments at fair value]. The principal accounting policies adopted are set out below.

1.2
Turnover

Turnover is recognised at the fair value of the consideration received or receivable for goods and services provided in the normal course of business, and is shown net of VAT and other sales related taxes. The fair value of consideration takes into account trade discounts, settlement discounts and volume rebates.

When cash inflows are deferred and represent a financing arrangement, the fair value of the consideration is the present value of the future receipts. The difference between the fair value of the consideration and the nominal amount received is recognised as interest income.

1.3
Intangible fixed assets - goodwill

Goodwill represents the excess of the cost of acquisition of unincorporated businesses over the fair value of net assets acquired. It is initially recognised as an asset at cost and is subsequently measured at cost less accumulated amortisation and accumulated impairment losses. Goodwill is considered to have a finite useful life and is amortised on a systematic basis over its expected life, which is five years.

1.4
Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Fixtures and fittings
10% on reducing balance

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.

1.5
Cash and cash equivalents

Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

BRENT PHARMA LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025
1
Accounting policies
(Continued)
- 4 -
1.6
Taxation

The tax expense represents the sum of the tax currently payable and deferred tax.

Current tax

The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the profit and loss account because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The company’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.

Deferred tax

Deferred tax liabilities are generally recognised for all timing differences and deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Such assets and liabilities are not recognised if the timing difference arises from goodwill or from the initial recognition of other assets and liabilities in a transaction that affects neither the tax profit nor the accounting profit.

The carrying amount of deferred tax assets is reviewed at each reporting end date and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered. Deferred tax is calculated at the tax rates that are expected to apply in the period when the liability is settled or the asset is realised. Deferred tax is charged or credited in the profit and loss account, except when it relates to items charged or credited directly to equity, in which case the deferred tax is also dealt with in equity. Deferred tax assets and liabilities are offset when the company has a legally enforceable right to offset current tax assets and liabilities and the deferred tax assets and liabilities relate to taxes levied by the same tax authority.

1.7
Retirement benefits

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

2
Employees

The average monthly number of persons (including directors) employed by the company during the year was:

2025
2024
Number
Number
Total
3
5
BRENT PHARMA LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025
- 5 -
3
Intangible fixed assets
Goodwill
£
Cost
At 1 April 2024 and 31 March 2025
125,000
Amortisation and impairment
At 1 April 2024 and 31 March 2025
124,999
Carrying amount
At 31 March 2025
1
At 31 March 2024
1
4
Tangible fixed assets
Fixtures and fittings
£
Cost
At 1 April 2024
17,390
Additions
2,697
At 31 March 2025
20,087
Depreciation and impairment
At 1 April 2024
5,193
Depreciation charged in the year
1,489
At 31 March 2025
6,682
Carrying amount
At 31 March 2025
13,405
At 31 March 2024
12,197
5
Debtors
2025
2024
Amounts falling due within one year:
£
£
Trade debtors
66,618
60,646
Other debtors
183,179
195,392
249,797
256,038
BRENT PHARMA LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025
- 6 -
6
Creditors: amounts falling due within one year
2025
2024
£
£
Trade creditors
113,481
107,291
Taxation and social security
42,451
36,674
Other creditors
206,704
169,766
362,636
313,731
7
Related party transactions
Transactions with related parties

During the year the company entered into the following transactions with related parties:

The following amounts were outstanding at the reporting end date:

2025
2024
Amounts due from related parties
£
£
Entities with common controlling shareholders and directors
169,600
167,600

The above disclosed amount is included within the other debtors due in one year. The loan is unsecured, interest free, and repayable on demand.

2025-03-31 2024-04-01 false false false 17 November 2025 CCH Software CCH Accounts Production 2025.200 No description of principal activity Mr M Shamoon 11277994 2024-04-01 2025-03-31 11277994 2025-03-31 11277994 2024-03-31 11277994 core:NetGoodwill 2025-03-31 11277994 core:NetGoodwill 2024-03-31 11277994 core:FurnitureFittings 2025-03-31 11277994 core:FurnitureFittings 2024-03-31 11277994 core:CurrentFinancialInstruments core:WithinOneYear 2025-03-31 11277994 core:CurrentFinancialInstruments core:WithinOneYear 2024-03-31 11277994 core:ShareCapital 2025-03-31 11277994 core:ShareCapital 2024-03-31 11277994 core:RetainedEarningsAccumulatedLosses 2025-03-31 11277994 core:RetainedEarningsAccumulatedLosses 2024-03-31 11277994 bus:Director1 2024-04-01 2025-03-31 11277994 core:Goodwill 2024-04-01 2025-03-31 11277994 core:FurnitureFittings 2024-04-01 2025-03-31 11277994 2023-04-01 2024-03-31 11277994 core:NetGoodwill 2024-03-31 11277994 core:FurnitureFittings 2024-03-31 11277994 core:CurrentFinancialInstruments 2025-03-31 11277994 core:CurrentFinancialInstruments 2024-03-31 11277994 core:WithinOneYear 2025-03-31 11277994 core:WithinOneYear 2024-03-31 11277994 bus:PrivateLimitedCompanyLtd 2024-04-01 2025-03-31 11277994 bus:SmallCompaniesRegimeForAccounts 2024-04-01 2025-03-31 11277994 bus:FRS102 2024-04-01 2025-03-31 11277994 bus:AuditExemptWithAccountantsReport 2024-04-01 2025-03-31 11277994 bus:FullAccounts 2024-04-01 2025-03-31 xbrli:pure xbrli:shares iso4217:GBP